

S 898

Fair Accountability and Innovative Research Drug Pricing Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Mar 23, 2021

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Mar 23, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/898>

Sponsor

Name: Sen. Baldwin, Tammy [D-WI]

Party: Democratic • **State:** WI • **Chamber:** Senate

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Braun, Mike [R-IN]	R · IN		Mar 23, 2021
Sen. Murkowski, Lisa [R-AK]	R · AK		Mar 23, 2021
Sen. Smith, Tina [D-MN]	D · MN		Mar 23, 2021
Sen. Hoeven, John [R-ND]	R · ND		Jun 9, 2021
Sen. King, Angus S., Jr. [I-ME]	I · ME		Jun 9, 2021

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Mar 23, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 9655	Related bill	Dec 21, 2022: Referred to the Committee on Ways and Means, and in addition to the Committees on Energy and Commerce, the Judiciary, Natural Resources, Education and Labor, and House Administration, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
117 HR 19	Related bill	Oct 19, 2021: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Fair Accountability and Innovative Research Drug Pricing Act of 2021

This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least \$100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.

Actions Timeline

- **Mar 23, 2021:** Introduced in Senate
- **Mar 23, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.